Lord, Abbett & Co
COGT icon

Lord, Abbett & Co’s Cogent Biosciences COGT Stock Holding History

Lord, Abbett & Co’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$133M Buy
3,431,030
+249,760
+8% +$8.74M 0.38% 64
2026
Q1 		$122M Buy
3,181,270
+1,310,733
+70% +$48.4M 0.4% 66
2025
Q4 		$66.4M Buy
+1,870,537
New +$52.6M 0.2% 131

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lord, Abbett & Co's COGT Position: Q2 2026 in Review

Lord, Abbett & Co increased its Cogent Biosciences (COGT) stake by 7.9% in Q2 2026, buying an estimated $8.74M and bringing the position to 3,431,030 shares worth $133M. The position accounts for 0.38% of the portfolio, ranked #64.

Lord, Abbett & Co first reported a position in COGT in Q4 2025 and has held it in 3 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Lord, Abbett & Co held 3,431,030 shares of Cogent Biosciences worth $133M as of Q2 2026.
  • Lord, Abbett & Co bought 249,760 Cogent Biosciences shares in Q2 2026, an estimated $8.74M.
  • Cogent Biosciences made up 0.38% of Lord, Abbett & Co's portfolio in Q2 2026, its #64 holding.
  • Lord, Abbett & Co first reported a position in Cogent Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.